https://scholars.lib.ntu.edu.tw/handle/123456789/627206
標題: | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | 作者: | Kelley, Robin Kate Rimassa, Lorenza ANN-LII CHENG Kaseb, Ahmed Qin, Shukui Zhu, Andrew X Chan, Stephen L Melkadze, Tamar Sukeepaisarnjaroen, Wattana Breder, Valery Verset, Gontran Gane, Edward Borbath, Ivan Rangel, Jose David Gomez Ryoo, Baek-Yeol Makharadze, Tamta Merle, Philippe Benzaghou, Fawzi Banerjee, Kamalika Hazra, Saswati Fawcett, Jonathan Yau, Thomas |
關鍵字: | RENAL-CELL CARCINOMA; BEVACIZUMAB; COMBINATION | 公開日期: | 八月-2022 | 出版社: | ELSEVIER SCIENCE INC | 卷: | 23 | 期: | 8 | 起(迄)頁: | 995 | 來源出版物: | The Lancet. Oncology | 摘要: | Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627206 | ISSN: | 1470-2045 | DOI: | 10.1016/S1470-2045(22)00326-6 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。